Fanapt™ is Granted Market Approval in Israel for the Treatment of Schizophrenia
11:13 EDT 9 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
WASHINGTON, Aug. 9, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announc...
Other Sources for this Article
More From BioPortfolio on "Fanapt™ is Granted Market Approval in Israel for the Treatment of Schizophrenia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
